Jami Rubin is a Partner in the Advisory Group at PJT Partners, based in New York. Prior to joining PJT Partners, Ms. Rubin spent over 25 years as an equity analyst following large cap and specialty pharmaceutical companies. Most recently, she was a Partner at Goldman Sachs, leading the healthcare business unit and a top ranked pharmaceutical industry analyst where she was responsible for managing the global team and making recommendations to institutional investors. She was most known for her advocacy of maximizing value through mergers & acquisitions, spin-offs and break-ups, with many companies following her advice, including Pfizer’s acquisition of Wyeth, followed by its spin-out of Zoetis, Abbott’s spin-out of AbbVie and Eli Lilly’s spin-out of Elanco. Ms. Rubin received her BA in History from Vassar College. She serves as an Independent Board member of Relay Therapeutics, a private biotech precision medicine company and Gilda’s Club NYC.